Novartis bets on Texas as radioligand therapy moves closer to mainstream oncology
RLT demand is rising faster than supply chains can stretch. Novartis’ Texas buildout tests whether precision oncology can scale.
What TAG1’s Lead-212 supply deal with Dana-Farber reveals about the future of radiopharmaceutical oncology
TAG1 and Dana-Farber partner to expand Lead-212 access for targeted alpha therapies. Discover what this means for radiopharmaceutical oncology innovation.